TITLE

Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation

AUTHOR(S)
Takahashi, M; Saito, T; Ito, M; Tsukada, C; Katono, Y; Hosono, H; Maekawa, M; Shimada, M; Mano, N; Oda, A; Hirasawa, N; Hiratsuka, M
PUB. DATE
February 2015
SOURCE
Pharmacogenomics Journal;Feb2015, Vol. 15 Issue 1, p26
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Genetic variations in cytochrome P450 2C19 (CYP2C19) contribute to interindividual variability in the metabolism of therapeutic agents such as clopidogrel. Polymorphisms in CYP2C19 are associated with large interindividual variations in the therapeutic efficacy of clopidogrel. This study evaluated the in vitro oxidation of clopidogrel by 21 CYP2C19 variants harboring amino acid substitutions. These CYP2C19 variants were heterologously expressed in COS-7 cells, and the kinetic parameters of clopidogrel 2-oxidation were estimated. Among the 21 CYP2C19 variants, 12 (that is, CYP2C19.5A, CYP2C19.5B, CYP2C19.6, CYP2C19.8, CYP2C19.9, CYP2C19.10, CYP2C19.14, CYP2C19.16, CYP2C19.19, CYP2C19.22, CYP2C19.24 and CYP2C19.25) showed no or markedly low activity compared with the wild-type protein CYP2C19.1B. This comprehensive in vitro assessment provided insights into the specific metabolic activities of CYP2C19 proteins encoded by variant alleles, and this may to be valuable when interpreting the results of in vivo studies.
ACCESSION #
100574462

 

Related Articles

  • Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. Bains, Ripudaman K.; Mirna Kovacevic, Mirna; Plaster, Christopher A.; Ayele Tarekegn, Ayele; Bekele, Endashaw; Bradman, Neil N.; Thomas, Mark G. // BMC Genetics;2013, Vol. 14 Issue 1, p1 

    Background: Cytochrome P450 3A5 (CYP3A5) is an enzyme involved in the metabolism of many therapeutic drugs. CYP3A5 expression levels vary between individuals and populations, and this contributes to adverse clinical outcomes. Variable expression is largely attributed to four alleles, CYP3A5"1...

  • Genetic Polymorphisms of CYP2C8 in A Healthy Iranian Population. Ramazani, Ali; Ghaffari, Mahsa; Fakhri, Amir // British Journal of Medicine & Medical Research;4/1/2014, Vol. 4 Issue 10, p2081 

    Aim: The aims of this study were to genotype CYP2C8 in an Iranian population and compare their allelic frequencies with other ethnic groups. Study Site and Duration: Biotechnology Department, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran from June 2012 through May 2013....

  • Effect of CYP2C19 variants on clopidogrel.  // Internal Medicine Alert;11/17/2009 Supplement, p21 

    The article reports on the results of a study which investigates the effect of CYP2C19 or P450 2C19 metabolite variants on clopidogrel.

  • Thienopyridine-proton pump inhibitor drug interaction. Polli, Stephanie Inverso // Hem/Onc Today;11/10/2009, Vol. 10 Issue 21, p5 

    The article discusses issues related to the metabolism processes of clopidogrel involving cytochrome P450 (CYP).

  • Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Scott, S A; Sangkuhl, K; Stein, C M; Hulot, J‐S; Mega, J L; Roden, D M; Klein, T E; Sabatine, M S; Johnson, J A; Shuldiner, A R // Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p317 

    Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious...

  • Allelic distributions of CYP2D6 gene copy number variation in the Eastern Han Chinese population. Hai-hui Sheng; Ai-ping Zeng; Wen-xiang Zhu; Ren-fang Zhu; Hong-mei Li; Zhi-dong Zhu; Ying Qin; Wei Jin; Yan Liu; Yun-lan Du; Jian Sun; Hua-sheng Xiao // Acta Pharmacologica Sinica;Feb2007, Vol. 28 Issue 2, p279 

    Aim: The human cytochrome P450 2D6 (CYP2D6) gene copy number variation, involving CYP2D6 gene deletion ( CYP2D6*5) and duplication or multiduplication ( CYP2D6*×N), can result in reduced or increased metabolism of many clinically used drugs. The identification of CYP2D6*5 and CYP2D6*×N...

  • Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions. Tornio, A; Filppula, A M; Kailari, O; Neuvonen, M; Nyrönen, T H; Tapaninen, T; Neuvonen, P J; Niemi, M; Backman, J T // Clinical Pharmacology & Therapeutics;Oct2014, Vol. 96 Issue 4, p498 

    Cerivastatin and repaglinide are substrates of cytochrome P450 (CYP)2C8, CYP3A4, and organic anion-transporting polypeptide (OATP)1B1. A recent study revealed an increased risk of rhabdomyolysis in patients using cerivastatin with clopidogrel, warranting further studies on clopidogrel...

  • Paraoxonase-1 and clopidogrel efficacy. Dansette, Patrick M; Rosi, Julien; Bertho, Gildas; Mansuy, Daniel // Nature Medicine;Sep2011, Vol. 17 Issue 9, p1040 

    A letter to the editor is presented concerning the dependence of cytochrome P450 (CYP) in paraoxonase-1 (PON1) and the role of PON1 in the efficacy of clopidogrel drug.

  • Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care. Rothenbacher, Dietrich; Hoffmann, Michael M.; Breitling, Lutz P.; Rajman, Iris; Koenig, Wolfgang; Brenner, Hermann // BMC Cardiovascular Disorders;2013, Vol. 13 Issue 1, p1 

    Background: CYP2C19"2 polymorphism is related to metabolizer phenotypes resulting in reduced effectiveness in converting the antiplatelet drug clopidogrel to active drug. An association of the genotype itself with adverse outcomes is discussed. We investigated the prognostic value of carriage of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics